NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company which develops, manufactures and markets life-saving medicines, announces that following discussions with the EMEA (European Agency for the Evaluation of Medicinal Products), the company will soon start phase II clinical trials with the inhaled version of its Alpha-1 Antitrypsin (AAT) product to treat Cystic Fibrosis (CF). Planning for the next phase (phase III) of clinical trials will begin pending successful completion of the second phase.
